At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed metastatic renal cell cancer with >75% clear cell histology
- ✓At least one unidimensionally measurable lesion ≥20 mm by conventional imaging or ≥10 mm by spiral CT
- ✓Nominally 'good' or 'intermediate' risk disease meeting ≥4 out of 5 prognostic criteria (hemoglobin >10 g/dL, ECOG 0-1, normal calcium, primary tumor treated, LDH <1.5×ULN)
- ✓No prior refractory disease (defined as progression during or within 3 months after IL-2)
- ✕Prior bevacizumab therapy
- ✕History of allergic reaction to antibody drugs or IL-2
- ✕Insulin-dependent diabetes
- ✕Known HIV positivity
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Trial of Sequential Bevacizumab Then Subcutaneous Interleukin-2 in Metastatic Renal Cancer
In Brief
A Phase 2 clinical trial evaluating Aldesleukin, Bevacizumab, and 1 other intervention for Recurrent Renal Cell Carcinoma and Stage IV Renal Cell Cancer. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving bevacizumab together with interleukin-2 works in treating patients with metastatic kidney cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells to kill tumor cells. Giving bevacizumab together with interleukin-2 may kill more tumor cells.
Study Details
Timeline
Interventions
Given subcutaneously
Given IV
Correlative studies